You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

Paliperidone palmitate versus oral risperidone and risperidone long-acting injection in patients with recently diagnosed schizophrenia: a tolerability and efficacy comparison

Fu, Dong-Jinga; Bossie, Cynthia A.a; Sliwa, Jennifer K.b; Ma, Yi-Wenc; Alphs, Larrya

International Clinical Psychopharmacology:
doi: 10.1097/YIC.0000000000000006
Original Articles
Abstract

Early in the course of illness, patients with schizophrenia may be particularly susceptible to adverse events (AEs). In this post-hoc, subgroup analysis of a 13-week, double-blind, double-dummy, multicenter study, patients recently diagnosed with schizophrenia (≤5 years) were administered once-monthly flexible-dose paliperidone palmitate (PP) (n=161; initiation doses, 150 mg eq day 1 and 100 mg eq day 8) [PP doses can be expressed as milligram equivalents (mg eq) of paliperidone or as milligrams (mg) of PP. 150 mg eq paliperidone=234 mg PP; 100 mg eq paliperidone=156 mg PP. In the USA, dosing tends to be expressed in mg] or oral risperidone [during initiation of risperidone long-acting injection (RLAI) days 1–28] and biweekly flexible-dose RLAI (n=173; initial injection day 8). Assessments were performed at baseline and days 4, 15, 22, 36, 64, and 92. Because of RLAI’s release profile, data through day 22 correspond to oral risperidone in the RLAI arm. During this period, the AE profile and onset of efficacy of PP and oral risperidone were similar. The overall AE rates at week 13 for PP and RLAI were 54.7 and 50.3%, respectively, for any AE; 11.2 and 8.1% for extrapyramidal symptom–related AEs; and 2.5 and 2.3% for prolactin-related AEs. No significant differences in the mean weight change, most metabolic parameters, or mean efficacy measures were observed at end point. In patients with recently diagnosed schizophrenia, the tolerability and efficacy of PP and RLAI were generally similar over 13 weeks.

Author Information

aMedical Affairs

bMedical Information, Janssen Scientific Affairs, LLC

cBiostatistics, B&P, Janssen Research & Development, LLC, Titusville, New Jersey, USA

These data were presented at the 13th International Congress on Schizophrenia Research; 2–6 April 2011; Colorado Springs, Colorado, USA.

Correspondence to Dong-Jing Fu, MD, PhD, Medical Affairs, Janssen Scientific Affairs, LLC, 1125 Trenton-Harbourton Road, Titusville, NJ 08650, USA Tel: +1 609 730 4312; fax: +1 609 730 3125; e-mail: dfu@its.jnj.com

Received March 15, 2013

Accepted August 22, 2013

© 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins